NO20045587L - Liposom vaksineformulering for finne-fisk - Google Patents

Liposom vaksineformulering for finne-fisk

Info

Publication number
NO20045587L
NO20045587L NO20045587A NO20045587A NO20045587L NO 20045587 L NO20045587 L NO 20045587L NO 20045587 A NO20045587 A NO 20045587A NO 20045587 A NO20045587 A NO 20045587A NO 20045587 L NO20045587 L NO 20045587L
Authority
NO
Norway
Prior art keywords
fish
vaccines
liposome
vaccine formulation
methods
Prior art date
Application number
NO20045587A
Other languages
English (en)
Other versions
NO335784B1 (no
Inventor
Christian Syvertsen
Kevin M W Keough
Original Assignee
Genesis Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesis Group Inc filed Critical Genesis Group Inc
Publication of NO20045587L publication Critical patent/NO20045587L/no
Publication of NO335784B1 publication Critical patent/NO335784B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det beskrives liposomvaksineformuleringer for fmne-fisk som omfatter antigenisk materiale avledet fra ett eller flere firm-fiskpatogener i assosiasjon med liposomer og som eventuelt inkluderer andre terapeutiske forbindelser. Vaksinene kan anvendes for immunisering og/eller for terapeutisk behandling av firme-fisk mot infeksiøse og parasittiske sykdommer. Vaksinene kan gi reduserte bivirkninger som mindre adhesjoner og pigmentering sammenlignet med oljebaserte vaksineformuleringer. Det besltrives videre fremgangsmåter for fremstilling og lagring av liposomvaksinene og metoder for adminisfrering av vaksineformuleringen til firme-fisk.
NO20045587A 2002-05-31 2004-12-22 Liposomvaksine omfattende antigenisk materiale fra finne-fisk patogener. NO335784B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38502802P 2002-05-31 2002-05-31
PCT/CA2003/000768 WO2003101482A2 (en) 2002-05-31 2003-05-30 Liposome vaccine formulations for fin-fish

Publications (2)

Publication Number Publication Date
NO20045587L true NO20045587L (no) 2004-12-22
NO335784B1 NO335784B1 (no) 2015-02-16

Family

ID=29712127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045587A NO335784B1 (no) 2002-05-31 2004-12-22 Liposomvaksine omfattende antigenisk materiale fra finne-fisk patogener.

Country Status (3)

Country Link
AU (1) AU2003229199A1 (no)
NO (1) NO335784B1 (no)
WO (1) WO2003101482A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2405003T3 (en) 2004-07-28 2015-09-21 Nat Res Council Canada Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
JP5054546B2 (ja) * 2006-02-07 2012-10-24 エヌエーアイ株式会社 新規ワクチン担体
CA2687208C (en) 2006-12-22 2017-02-14 Soluciones Biotecnologicas Innovacion Ltda Process and formulation for immunizing fish in aquaculture systems
ES2321789B1 (es) * 2007-03-02 2010-03-15 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) Utilizacion del vector pil8+ de trucha como inmunoestimulante o adyuvante para vacunas adn en peces.
WO2009070929A1 (en) * 2007-12-04 2009-06-11 Schweitzer Co., Ltd. A subunit vaccine for aquaculture
NO333242B1 (no) * 2008-02-08 2013-04-15 Pharmaq As Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus
CN107099496B (zh) * 2017-04-25 2021-04-13 中国农业科学院哈尔滨兽医研究所 融合表达鸡传染性法氏囊病毒vp2蛋白和沙门菌属外膜蛋白的重组乳酸菌菌株及其用途
CL2017003358A1 (es) * 2017-12-26 2018-06-22 Univ De Chile 50% Formulación de vacuna para peces en base a nanovesículas lipídicas, en especial, un proteoliposoma o cocleato, con actividad contra el síndrome rickettsial del salmón
CN111018955B (zh) * 2020-01-06 2021-10-26 济南大学 一种抑制病毒基因组rna复制的多肽
KR102458429B1 (ko) * 2021-03-18 2022-10-26 대한민국 바이러스성 출혈성 패혈증 예방을 위한 어류 경구백신용 리포좀 및 이의 제조방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140151A2 (en) * 1998-12-22 2001-10-10 Dalhousie University Compositions and methods for reducing or preventing fertilization in fish and birds

Also Published As

Publication number Publication date
WO2003101482A3 (en) 2004-02-05
NO335784B1 (no) 2015-02-16
AU2003229199A1 (en) 2003-12-19
AU2003229199A8 (en) 2003-12-19
WO2003101482A2 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
NO20040258L (no) Preparat for behandling av negleinfeksjoner med nitrogenoksid
NO20015073L (no) Vaksiner
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
NO20045587L (no) Liposom vaksineformulering for finne-fisk
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
IL311855A (en) Immunogenic lnp compositions and methods thereof
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
BRPI0418157A (pt) terapêutica de tumores alogênicos
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
CY1121921T1 (el) Φαρμακευτικα σκευασματα
CY1120793T1 (el) Μεθοδοι θεραπευτικης αγωγης παθησεων που αφορουν μαλλια
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
DE60330004D1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
ATE359815T1 (de) Streptococcus-phocae-vakzine
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
DE602005021873D1 (de) Neues impfstoffadjuvans und dessen herstellung und verwendung
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
MX2023000097A (es) Adyuvantes de vacunas y metodos de sintetizacion y uso de estos.
CA3292453A1 (en) Compounds and formulations useful as vaccine adjuvants

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 1813 VIKA, 0123 OSLO, NORGE

MK1K Patent expired